FLT3 and acute myeloid leukemia: Cellular heterogeneity plays a pivotal role in the varying drug responses observed in AML patients, as distinct cell populations exhibit different therapeutic responses.[23] To identify cell types sensitive to FLT3 inhibition, we applied the EPIC[24] method to infer the proportions of 11 leukemic cell types in pre‐therapy bulk RNA samples from the BeatAML cohort.